ATLANTA, Feb. 21, 2012 /PRNewswire/ -- Acella Pharmaceuticals, LLC, recently announced that it has filed an abbreviated new drug application (ANDA) for a product in the upper respiratory therapeutic area with the U.S. Food and Drug Administration (FDA). This filing represents the 5th ANDA Acella has waiting approval from the FDA, and the first filed under the leadership of Allen Fields, Acella’s new VP, Head of Research and Development.
“We are pleased with the FDA’s acceptance of our filing,” remarked Fields. “I believe this latest filing speaks to the quality of work performed by our team, as well as to our continuous efforts to develop a strong pipeline of products for our internal and external customers.”
“This filing is another example of our investment in new products and expansion of our diversified product portfolio,” added Acella CEO Mark Pugh. “As always, Acella is committed to making quality healthcare more affordable for our customers.”
About Acella Pharmaceuticals, LLC
Acella develops, markets, sells and distributes a broad portfolio of specialty pharmaceutical and other products in the areas of Dermatology, Women’s Health, Pediatrics and other applications. Acella specializes in identifying and bringing to market quality, affordable products to customers and patients. For additional information please contact Acella at 678-325-5189.
SOURCE Acella Pharmaceuticals, LLC
